Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best get rich quick stocks to buy now. Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with an Outperform rating and a price target of $11, implying an upside potential of nearly 326%. This optimism is derived from the company’s lead drug candidate, BDTX-1535, which has demonstrated promising results in patients already treated with osimertinib.

The research firm views this efficacy as an improved first-line treatment setting, mainly for patients with non-classical mutations, where ongoing treatments have limited effectiveness. What’s even interesting is that Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) targets a niche market through BDTX-1535 in contrast to large enterprises working to address a broad range of EGFR mutations. This means that the company is prioritizing selectivity over wild-type EGFR while offering greater activity against atypical mutations.

A close-up of a chemist examining a vial of a small molecule inhibitor for oncogenic proteins.

Additionally, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) exhibits robust financials, with a cash runway adequate till at least the last quarter of FY27, thus allowing the company to maintain flexibility to lead a first-line non-small cell lung cancer study in non-classical mutations upon FDA feedback.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), based in Massachusetts, is a clinical-stage oncology company that identifies and develops MasterKey therapies targeting patients with genetically defined tumors. Founded in 2014, the company is committed to making a significant impact on oncology through innovative science.

While we acknowledge the potential of BDTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BDTX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.